GO:1902072 negative regulation of hypoxia-inducible factor-1alpha signaling pathway: Mechanism, Genes and Research Methods
Research-grade guide for scientists and biopharma professionals
Key Takeaways
• GO:1902072 describes any process that stops, prevents, or reduces the frequency, rate, or extent of hypoxia-inducible factor-1alpha (HIF-1alpha) signaling.
• HIF-1alpha is a master regulator of oxygen homeostasis, and its negative regulation is critical for preventing excessive angiogenesis, metabolic reprogramming, and inflammation [1, 2].
• Key negative regulators include SIRT2, Sestrin2, and Pik3ip1, which modulate HIF-1alpha stability or activity through distinct mechanisms [4, 6, 8].
• Dysregulation of HIF-1alpha negative regulation is implicated in cancer, diabetic kidney disease, autoimmune disorders, and bone metabolism [2, 3, 5, 7, 8].
• CRISPR-based models (knockout, point mutation, knock-in, overexpression) enable precise dissection of negative regulatory mechanisms [2, 4, 6].
• EDITGENE provides comprehensive CRISPR services to accelerate research on HIF-1alpha negative regulation and related therapeutic targets [2, 3, 8].
Description
The hypoxia-inducible factor-1alpha (HIF-1alpha) signaling pathway is a central mediator of cellular adaptation to low oxygen tension, driving transcriptional programs that promote angiogenesis, glycolysis, and survival [1, 2]. Under normoxic conditions, HIF-1alpha is rapidly degraded via the prolyl hydroxylase (PHD)-von Hippel-Lindau (VHL) axis, but hypoxia stabilizes HIF-1alpha, allowing it to accumulate and activate target genes [1, 6]. The Gene Ontology term GO:1902072, negative regulation of hypoxia-inducible factor-1alpha signaling pathway, encompasses any process that stops, prevents, or reduces the frequency, rate, or extent of this signaling cascade. This term is essential for understanding how cells fine-tune HIF-1alpha activity to avoid pathological outcomes such as tumor progression, chronic inflammation, and metabolic disorders [2, 3, 8]. Research into GO:1902072 has revealed diverse molecular mechanisms, including oxygen-dependent degradation, post-translational modifications, and feedback loops involving metabolic intermediates like succinate [1, 4, 6]. For example, succinate acts as an inflammatory signal that induces IL-1beta through HIF-1alpha, highlighting the interplay between metabolism and HIF-1alpha regulation. SIRT2 inhibition activates HIF-1alpha signaling and mediates neuronal survival, demonstrating that negative regulation can be modulated pharmacologically. Sestrin2 inhibits HIF-1alpha accumulation via AMPK-mediated prolyl hydroxylase regulation, linking cellular stress responses to HIF-1alpha suppression. These findings underscore the importance of negative regulation in maintaining cellular homeostasis and suggest therapeutic opportunities [2, 8]. Given the broad impact of HIF-1alpha signaling on human health, understanding its negative regulation is crucial for developing targeted interventions [2, 3, 5, 7]. This article synthesizes current knowledge on GO:1902072, covering its definition, mechanisms, key genes, disease relevance, and research methodologies, with a focus on CRISPR-based approaches for functional validation [2, 4, 6, 8].
negative regulation of hypoxia-inducible factor-1alpha signaling pathway At A Glance
| GO ID | GO:1902072 |
|---|---|
| GO term | negative regulation of hypoxia-inducible factor-1alpha signaling pathway |
| Ontology | biological_process |
| Synonym | inhibition of HIF1alpha pathway; downregulation of hypoxia-inducible factor-1alpha signaling pathway; negative regulation of HIF1alpha pathway |
| Major function | Suppression of HIF-1alpha signaling to prevent excessive angiogenesis, metabolic reprogramming, and inflammation [1, 2]. |
| Key regulators | SIRT2, Sestrin2, Pik3ip1, prolyl hydroxylases, VHL [4, 6, 8]. |
| Associated diseases | Triple-negative breast cancer, diabetic kidney disease, autoimmune disease, bone disorders [2, 3, 5, 7, 8]. |
| Research methods | CRISPR knockout, point mutation, knock-in, overexpression, proteomics, lipidomics [2, 3, 4, 6, 8]. |
What Is GO:1902072?
GO:1902072, negative regulation of hypoxia-inducible factor-1alpha signaling pathway, is a biological process defined as any process that stops, prevents, or reduces the frequency, rate, or extent of hypoxia-inducible factor-1alpha signaling pathway. This includes mechanisms that destabilize HIF-1alpha protein, inhibit its transcriptional activity, or interfere with upstream or downstream components of the pathway [1, 4, 6].
Why Is negative regulation of hypoxia-inducible factor-1alpha signaling pathway Important in Cell Biology?
Negative regulation of HIF-1alpha signaling is vital for preventing pathological conditions driven by excessive HIF-1alpha activity, such as cancer, chronic inflammation, and metabolic diseases [1, 2, 3, 8]. Understanding this process provides insights into cellular oxygen sensing and offers therapeutic targets for modulating HIF-1alpha in disease contexts [2, 4, 6].
• Prevents excessive angiogenesis and vascular leakage in normoxic tissues [1, 2].
• Limits inflammatory responses by controlling HIF-1alpha-driven IL-1beta production.
• Regulates metabolic reprogramming in immune cells and cancer cells [2, 8].
• Protects against diabetic kidney disease by mitigating ferroptosis.
• Modulates neuronal survival under stress conditions.
• Influences bone mass accrual through HIF-2alpha and HIF-1alpha interplay [5, 7].
• Provides targets for therapeutic intervention in triple-negative breast cancer.
• Serves as a paradigm for oxygen-sensing mechanisms in physiology [1, 6].
What Happens During negative regulation of hypoxia-inducible factor-1alpha signaling pathway?
Oxygen-Dependent Degradation of HIF-1alpha
In simple terms: When oxygen is available, HIF-1alpha is tagged for destruction.
Under normoxic conditions, prolyl hydroxylases (PHDs) hydroxylate specific proline residues on HIF-1alpha, enabling recognition by the von Hippel-Lindau (VHL) E3 ubiquitin ligase complex, which targets HIF-1alpha for proteasomal degradation [1, 6]. This oxygen-dependent degradation is a primary mechanism of negative regulation. Sestrin2 has been shown to inhibit HIF-1alpha accumulation via AMPK-mediated regulation of prolyl hydroxylases, further linking cellular stress to HIF-1alpha suppression.
Post-Translational Modifications and Stability
In simple terms: Chemical tags on HIF-1alpha can block its activity.
Beyond hydroxylation, other post-translational modifications such as acetylation, phosphorylation, and SUMOylation modulate HIF-1alpha stability and transcriptional activity [4, 6]. SIRT2 inhibition activates HIF-1alpha signaling, indicating that sirtuin-mediated deacetylation may contribute to negative regulation under certain conditions. These modifications provide additional layers of control independent of oxygen levels.
Feedback Inhibition by Metabolic Intermediates
In simple terms: Metabolites can act as signals to turn down HIF-1alpha.
The tricarboxylic acid (TCA) cycle intermediate succinate acts as an inflammatory signal that induces IL-1beta through HIF-1alpha, revealing a feedback loop where metabolic stress can influence HIF-1alpha activity. This suggests that negative regulation of HIF-1alpha may involve sensing of metabolic intermediates, although the precise mechanisms remain to be fully elucidated.
Regulation by Signaling Pathways
In simple terms: Other cellular pathways can put the brakes on HIF-1alpha.
The PI3K/Akt/mTOR pathway is a well-known positive regulator of HIF-1alpha, but negative regulation can occur through phosphatases or inhibitors such as Pik3ip1, which regulates autoimmune disease progression through metabolic reprogramming in T cells. Additionally, AMPK activation by Sestrin2 leads to prolyl hydroxylase regulation and HIF-1alpha inhibition. These examples illustrate crosstalk between HIF-1alpha and other signaling networks.
Key Genes Involved in GO:1902072 negative regulation of hypoxia-inducible factor-1alpha signaling pathway
The following genes and proteins are key players in the negative regulation of HIF-1alpha signaling, based on published literature.
| Gene | Major Role | Research Relevance |
|---|---|---|
| VHL | E3 ubiquitin ligase targeting HIF-1alpha for degradation | Mutations cause von Hippel-Lindau disease; model for oxygen sensing [1, 6] |
| EGLN1 (PHD2) | Prolyl hydroxylase that hydroxylates HIF-1alpha | Oxygen sensor; target for modulating HIF-1alpha stability [1, 6] |
| SIRT2 | Deacetylase that can inhibit HIF-1alpha signaling | Inhibition activates HIF-1alpha and promotes neuronal survival |
| SESN2 (Sestrin2) | Inhibits HIF-1alpha accumulation via AMPK-mediated PHD regulation | Links stress response to HIF-1alpha suppression |
| PIK3IP1 | Negative regulator of PI3K/Akt pathway, affecting HIF-1alpha | Regulates autoimmune disease progression via metabolic reprogramming |
| HIF1A | Alpha subunit of HIF-1 transcription factor | Central to hypoxia response; subject to negative regulation [1, 2] |
| EPAS1 (HIF-2alpha) | Homolog of HIF-1alpha with distinct roles | Negative regulator of osteoblastogenesis and bone mass |
| PTH | Parathyroid hormone | Its anabolic actions are restricted by HIF-1alpha |
| IL1B | Interleukin-1 beta | Induced by succinate through HIF-1alpha |
| HMOX1 | Heme oxygenase 1 | Downstream target in HIF-1alpha pathway; involved in ferroptosis |
| AMPK | Energy sensor kinase | Mediates Sestrin2 effects on HIF-1alpha |
| MTOR | Mechanistic target of rapamycin | Positive regulator of HIF-1alpha, crosstalk with negative regulators |
| AKT1 | Serine/threonine kinase | Upstream of HIF-1alpha; modulated by Pik3ip1 |
| NFKB1 | Nuclear factor kappa B | Inflammatory signaling crosstalk with HIF-1alpha |
| STAT3 | Signal transducer and activator of transcription 3 | Potential modulator of HIF-1alpha transcription |
| EP300 | Histone acetyltransferase p300 | Coactivator of HIF-1alpha; negative regulation may involve its inhibition |
| CREBBP | CREB-binding protein | Similar to EP300, coactivator of HIF-1alpha |
| ARNT | Aryl hydrocarbon receptor nuclear translocator (HIF-1beta) | Dimerization partner of HIF-1alpha; negative regulation may affect dimerization |
How Is negative regulation of hypoxia-inducible factor-1alpha signaling pathway Regulated?
The negative regulation of HIF-1alpha signaling is itself subject to regulation by various cellular pathways. For instance, AMPK activation by Sestrin2 leads to increased prolyl hydroxylase activity, promoting HIF-1alpha degradation. Conversely, inhibition of SIRT2 activates HIF-1alpha signaling, suggesting that sirtuin activity normally contributes to negative regulation. The PI3K/Akt/mTOR pathway, often activated in cancer, can overcome negative regulation by enhancing HIF-1alpha translation. Additionally, metabolic intermediates like succinate can modulate HIF-1alpha activity, indicating a complex interplay between metabolism and oxygen sensing.
negative regulation of hypoxia-inducible factor-1alpha signaling pathway and Human Disease
| Gene | Disease / Biology | Potential Experimental Model |
|---|---|---|
| HIF1A | Triple-negative breast cancer | Knockout or overexpression in breast cancer cell lines |
| VHL | Von Hippel-Lindau disease | Point mutation knock-in in renal cells [1, 6] |
| SIRT2 | Neurodegeneration | Knockout or inhibitor treatment in neuronal cultures |
| SESN2 | Metabolic stress | Overexpression in hepatocytes or cancer cells |
| PIK3IP1 | Autoimmune disease | Knockout in T cells |
Cancer
Dysregulation of HIF-1alpha negative regulation is common in cancer, where hypoxia drives tumor progression and resistance to therapy. In triple-negative breast cancer, targeting HIF-1alpha has emerged as a new strategy, highlighting the importance of understanding its negative regulation. Loss of VHL or PHD function leads to constitutive HIF-1alpha activation, promoting angiogenesis and metabolic reprogramming [1, 6].
Diabetic Kidney Disease
In diabetic kidney disease, HIF-1alpha signaling contributes to ferroptosis in renal tubular epithelial cells. Astragaloside IV mitigates ferroptosis through the HIF-1alpha/heme oxygenase 1 pathway, suggesting that negative regulation of HIF-1alpha could be protective.
Autoimmune Disease
Pik3ip1 regulates autoimmune disease progression through metabolic reprogramming in T cells, in part by modulating HIF-1alpha signaling. This indicates that negative regulation of HIF-1alpha is important for immune homeostasis.
Bone Metabolism
HIF-1alpha restricts the anabolic actions of parathyroid hormone, and HIF-2alpha is a negative regulator of osteoblastogenesis and bone mass accrual [5, 7]. These findings link HIF-1alpha negative regulation to bone health.
From negative regulation of hypoxia-inducible factor-1alpha signaling pathway-Related Genes to Experimental Models
| Research Question | Suitable Model |
|---|---|
| Does gene X negatively regulate HIF-1alpha? | CRISPR knockout of gene X followed by HIF-1alpha reporter assay [2, 4] |
| Does a specific point mutation in VHL affect HIF-1alpha degradation? | Point mutation knock-in of VHL in cell lines [1, 6] |
| Can a tag help visualize HIF-1alpha regulation? | Knock-in of fluorescent tag at HIF1A locus |
| Does overexpression of Sestrin2 inhibit HIF-1alpha? | Overexpression of SESN2 in cancer cells |
| What is the role of Pik3ip1 in T cell metabolism? | Knockout of PIK3IP1 in primary T cells |
| Does SIRT2 inhibition activate HIF-1alpha? | CRISPR knockout of SIRT2 or pharmacological inhibition |
How to Study the negative regulation of hypoxia-inducible factor-1alpha signaling pathway Process
| Method | What It Measures | Typical Application |
|---|---|---|
| CRISPR knockout | Loss-of-function of candidate genes | Identify negative regulators of HIF-1alpha [2, 4] |
| CRISPR activation (CRISPRa) | Gain-of-function of candidate genes | Discover suppressors of HIF-1alpha signaling |
| RNA-seq | Transcriptional changes | Assess HIF-1alpha target gene expression [1, 3] |
| Proteomics | Protein abundance and modifications | Identify HIF-1alpha interacting proteins |
| Luciferase reporter | HIF-1alpha transcriptional activity | Screen for modulators of HIF-1alpha [1, 4] |
| Immunoblotting | HIF-1alpha protein levels | Validate degradation or stabilization |
| Immunofluorescence | Subcellular localization | Visualize HIF-1alpha nuclear translocation |
| Metabolomics | Metabolite levels | Link HIF-1alpha to metabolic pathways |
CRISPR-Based Genetic Screens
Genome-wide CRISPR knockout or activation screens can identify novel negative regulators of HIF-1alpha signaling. For example, a screen could use a HIF-1alpha-responsive reporter to select cells with altered HIF-1alpha activity [2, 4].
Proteomics and Lipidomics
Proteomic and lipidomic analyses have been used to dissect the mechanism of astragaloside IV in mitigating ferroptosis through the HIF-1alpha/heme oxygenase 1 pathway, revealing downstream effects of HIF-1alpha regulation.
Reporter Assays and Imaging
HIF-1alpha transcriptional activity can be measured using luciferase reporters driven by hypoxia response elements (HREs). Imaging of HIF-1alpha localization or stability using fluorescent tags provides spatial and temporal information [1, 4].
Metabolic Profiling
Since HIF-1alpha is linked to metabolic reprogramming, Seahorse extracellular flux analysis and metabolomics can assess how negative regulators affect glycolysis and oxidative phosphorylation.
How CRISPR Can Be Used to Study GO:1902072 negative regulation of hypoxia-inducible factor-1alpha signaling pathway
Knockout
CRISPR knockout of candidate negative regulators (e.g., VHL, EGLN1, SIRT2) can confirm their role in suppressing HIF-1alpha signaling. For instance, knocking out SIRT2 would be expected to activate HIF-1alpha signaling, as observed with pharmacological inhibition. Knockout of SESN2 would likely increase HIF-1alpha accumulation.
Point Mutation
Point mutations can mimic disease-associated variants or disrupt specific post-translational modification sites. For example, mutating the proline residues in HIF-1alpha that are hydroxylated by PHDs would prevent VHL-mediated degradation, leading to constitutive HIF-1alpha activity [1, 6].
Knock-in
Knock-in of tags (e.g., GFP, luciferase) at the endogenous HIF1A locus allows real-time monitoring of HIF-1alpha stability and localization without overexpression artifacts. Knock-in of disease mutations in VHL can model von Hippel-Lindau disease.
Overexpression
Overexpression of negative regulators such as Sestrin2 or Pik3ip1 can suppress HIF-1alpha signaling and reverse pathological phenotypes. For example, overexpression of SESN2 inhibits HIF-1alpha accumulation via AMPK-mediated PHD regulation.
How EDITGENE Supports negative regulation of hypoxia-inducible factor-1alpha signaling pathway Research
Researchers studying negative regulation of hypoxia-inducible factor-1alpha signaling pathway-related genes often need to determine whether a candidate gene is causally involved in suppressing HIF-1alpha activity or is merely correlated with changes in expression. CRISPR-based models provide the gold standard for establishing causality, enabling precise genetic perturbations in relevant cell types.
Contact EDITGENE today to design your custom CRISPR model for negative regulation of hypoxia-inducible factor-1alpha signaling pathway research.
Frequently Asked Questions About negative regulation of hypoxia-inducible factor-1alpha signaling pathway
What is GO:1902072?
GO:1902072 is a Gene Ontology term for any process that stops, prevents, or reduces the frequency, rate, or extent of hypoxia-inducible factor-1alpha signaling pathway.
What genes are involved in negative regulation of HIF-1alpha signaling?
Key genes include VHL, EGLN1 (PHD2), SIRT2, SESN2 (Sestrin2), and PIK3IP1, among others [1, 4, 6, 8].
How does Sestrin2 inhibit HIF-1alpha?
Sestrin2 inhibits HIF-1alpha accumulation via AMPK-mediated regulation of prolyl hydroxylases.
What is the role of SIRT2 in HIF-1alpha signaling?
SIRT2 inhibition activates HIF-1alpha signaling and mediates neuronal survival, suggesting SIRT2 normally contributes to negative regulation.
How is HIF-1alpha degraded under normoxia?
Under normoxia, prolyl hydroxylases hydroxylate HIF-1alpha, leading to VHL-mediated ubiquitination and proteasomal degradation [1, 6].
What diseases are linked to defective HIF-1alpha negative regulation?
Cancer, diabetic kidney disease, autoimmune disease, and bone disorders are associated with dysregulated HIF-1alpha negative regulation [2, 3, 5, 7, 8].
Can CRISPR be used to study HIF-1alpha negative regulation?
Yes, CRISPR knockout, point mutation, knock-in, and overexpression models are powerful tools to dissect negative regulatory mechanisms [2, 4, 6, 8].
What is the connection between succinate and HIF-1alpha?
Succinate acts as an inflammatory signal that induces IL-1beta through HIF-1alpha, linking metabolism to HIF-1alpha regulation.
How does Pik3ip1 regulate HIF-1alpha?
Pik3ip1 regulates autoimmune disease progression through metabolic reprogramming in T cells, in part by modulating HIF-1alpha signaling.
What methods are used to measure HIF-1alpha activity?
Common methods include luciferase reporter assays, immunoblotting, immunofluorescence, RNA-seq, and proteomics [1, 3, 4, 6].
Conclusion
GO:1902072, negative regulation of hypoxia-inducible factor-1alpha signaling pathway, is a critical biological process that maintains cellular homeostasis by preventing excessive HIF-1alpha activity. Dysregulation of this process contributes to cancer, metabolic diseases, and inflammatory disorders [1, 2, 3, 8]. Advances in CRISPR-based models and multi-omics approaches are accelerating the discovery of novel negative regulators and therapeutic targets [2, 4, 6, 8]. EDITGENE's comprehensive services support researchers in dissecting these mechanisms with precision and efficiency.
References
- 1. Tannahill GM et al.. 2013. Succinate is an inflammatory signal that induces IL-1β through HIF-1α.. Nature 496(7444):238-42 PMID: 23535595
- 2. Liu Q et al.. 2022. Targeting hypoxia-inducible factor-1alpha: A new strategy for triple-negative breast cancer therapy.. Biomed Pharmacother 156:113861 PMID: 36228375
- 3. Liu J et al.. 2024. Proteomic and lipidomic analysis of the mechanism underlying astragaloside IV in mitigating ferroptosis through hypoxia-inducible factor 1α/heme oxygenase 1 pathway in renal tubular epithelial cells in diabetic kidney disease.. J Ethnopharmacol 334:118517 PMID: 38972525
- 4. Kaitsuka T et al.. 2020. SIRT2 inhibition activates hypoxia-inducible factor 1α signaling and mediates neuronal survival.. Biochem Biophys Res Commun 529(4):957-962 PMID: 32819605
- 5. Frey JL et al.. 2014. Hypoxia-inducible factor-1α restricts the anabolic actions of parathyroid hormone.. Bone Res 2:14005 PMID: 26273518
- 6. Seo K et al.. 2016. Sestrin2 inhibits hypoxia-inducible factor-1α accumulation via AMPK-mediated prolyl hydroxylase regulation.. Free Radic Biol Med 101:511-523 PMID: 27840318
- 7. Merceron C et al.. 2019. Hypoxia-inducible factor 2α is a negative regulator of osteoblastogenesis and bone mass accrual.. Bone Res 7:7 PMID: 30792937
- 8. Xie W et al.. 2022. Regulation of autoimmune disease progression by Pik3ip1 through metabolic reprogramming in T cells and therapeutic implications.. Sci Adv 8(39):eabo4250 PMID: 36179018
